Insigneo Advisory Services’s Pacific Biosciences PACB Stock Holding History

Insigneo Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.2K	Hold	18,595	–	–	﹤0.01%	838
2026 Q1	$24.5K	Buy	+18,595	New	+$33.3K	﹤0.01%	702

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Insigneo Advisory Services's PACB Position: Q2 2026 in Review

Insigneo Advisory Services held its Pacific Biosciences (PACB) position steady in Q2 2026 at 18,595 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #838.

Insigneo Advisory Services first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Insigneo Advisory Services held 18,595 shares of Pacific Biosciences worth $31.2K as of Q2 2026.
Insigneo Advisory Services left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Insigneo Advisory Services's portfolio in Q2 2026, its #838 holding.
Insigneo Advisory Services first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Insigneo Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.